Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Malignant Neoplasm × trametinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Melanoma 76 Neoplasms 37 Carcinoma, Non-Small-Cell Lung 26 Colorectal Neoplasms 17 Neoplasm Metastasis 15 Multiple Myeloma 11 Glioma 11 Thyroid Neoplasms 10 Thyroid Carcinoma, Anaplastic 9 Pancreatic Neoplasms 9 Hematologic Neoplasms 8 Brain Neoplasms 8 Lung Neoplasms 6 Triple Negative Breast Neoplasms 5 Skin Neoplasms 5 Neurofibromatosis 1 5 Astrocytoma 5 Recurrence 4 Rectal Neoplasms 4 Lymphoma 4 Glioblastoma 4 Colonic Neoplasms 4 Cholangiocarcinoma 4 Breast Neoplasms 4 Uveal Melanoma 3 Oligodendroglioma 3 Neurofibroma, Plexiform 3 Leukemia, Myeloid, Acute 3 Biliary Tract Neoplasms 3 Bile Duct Neoplasms 3

Interventions

trametinib 1 dabrafenib 1 Surgical Procedures, Operative 1 Pharmaceutical Preparations 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡